Kenvue Inc. (NYSE:KVUE) Position Boosted by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 4.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 262,992 shares of the company’s stock after acquiring an additional 12,082 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Kenvue were worth $5,662,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Clearstead Advisors LLC acquired a new stake in Kenvue in the third quarter worth about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue in the 4th quarter worth approximately $27,000. Global Retirement Partners LLC bought a new position in shares of Kenvue in the third quarter valued at approximately $28,000. Venturi Wealth Management LLC acquired a new position in shares of Kenvue during the third quarter valued at approximately $28,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Kenvue during the third quarter worth approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 0.8 %

NYSE KVUE traded down $0.16 on Friday, hitting $18.86. 15,451,237 shares of the stock were exchanged, compared to its average volume of 16,691,828. The company’s 50-day moving average price is $19.84 and its two-hundred day moving average price is $20.13. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 52-week low of $17.82 and a 52-week high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. On average, equities research analysts anticipate that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a $0.20 dividend. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 annualized dividend and a yield of 4.24%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. decreased their price target on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Friday, February 9th. Finally, William Blair initiated coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.